The quality of a country's disease surveillance system determines how much it knows about the health threats it faces and how quickly it can respond to them.
Why Surveillance Is Governance
Disease surveillance — the systematic collection, analysis, and reporting of health data to detect and respond to disease threats — is a governance function as much as a technical one. The quality of the surveillance system determines what the health system knows about disease burden, outbreak development, and population health trends. That knowledge is the foundation of every subsequent governance decision about how to allocate health resources, where to target interventions, and when to escalate the response to an emerging threat. A health governance system operating without adequate surveillance is governing without the information that governance requires.
Surveillance as Early Warning
The most consequential function of disease surveillance is early warning — the identification of emerging threats before they have reached the scale that makes response much more difficult and expensive. The COVID-19 pandemic supplied a natural experiment in the value of timing. A 148-country analysis of government stringency indices found that each day earlier to a high SI level from the start of response was associated with 0.44 days earlier to the peak number of daily new cases, a relationship that held after adjusting for region and initiation stage. The same dynamic showed up at the level of outcomes, not just curves: among Nordic countries, COVID-19 mortality per capita was 10 times higher in Sweden than in Finland and Norway, and five times higher than in Denmark over a comparable period, a gap the researchers linked to the timing and consistency of government response. Elsewhere, a comparative study of public health and social measures found that implementing a package of four measures — quarantine and isolation, school closures, household confinement, and limiting social gatherings — early and stringently coincided with lower case counts and transmission durations in Vietnam, Zimbabwe, New Zealand, South Korea, Ethiopia, and Kazakhstan, while the United States implemented few of these measures stringently or early.
None of this response, however, is possible without the surveillance data that tells decision-makers where the epidemic curve actually is. And the pandemic exposed how fragile that layer had become. A review of pandemic-preparedness lessons concluded that current surveillance approaches were designed and more suitable for monitoring of known pandemics or the ongoing surveillance for seasonal influenza than for the early detection of a pandemic-capable pathogen before widespread transmission. Country-level assessments told a similar story: a study of surveillance systems across the Democratic Republic of Congo, Nigeria, Senegal, and Uganda found that all countries reported inadequate staffing, staff capacity gaps and lack of full integration of data sources, and although all four improved data management and surveillance capacity, the disease burden was under-detected. Systems that looked adequate for endemic, well-characterized disease were not built for the speed and uncertainty that a novel pathogen demands.
Disease surveillance is among the health system's most consequential investments relative to its cost — because the early warning it provides determines whether a responding institution is ahead of or behind the threat it is managing. The evidence from COVID-19 suggests that days of lead time translate into measurably different epidemic curves and mortality outcomes. Being ahead is cheaper than being behind; the surveillance system is what makes it possible to know which one you are.
Discussion